RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies
These might include renal function, electrolytes, creatine kinase (to assess for muscle damage), and glucose monitoring
Diabetes affects an estimated 463 million individuals worldwide, a number that has quadrupled since 1980 (1)
Notice how 10 units at this concentration delivers the standard starting dose of 0.25 mg
The medications for treating high cholesterol Statins: These are the most common drugs for lowering cholesterol